MENU
Session 3: October 26, 2021 9:00 AM CDT

A Microsatellite Instability (MSI) Series

MSI has rapidly advanced as an important pan tumor biomarker associated with response to immune checkpoint inhibitors and the drive towards universal tumor testing. 

Join Session 3 to learn more about MSI from two esteemed speakers who will present on the following topics:

  • Performance of the industry's first and only PCR-based diagnostic kit for MSI characterization (FDA-cleared)
  • The most current clinical practice guidelines for MSI testing
  • MSI detection using PCR followed by capillary electrophoresis (CE) analysis
  • The clinical utility of the MSI biomarker for Lynch syndrome screening and immunotherapy treatment
  • Compare techniques used to measure MSI to current gold-standard methods

In addition to the presentations, you will have the opportunity to: 

  • Peruse our booth to view instrument demonstrations from our sample-to-answer workflow for MSI analysis
  • Connect with Promega Clinical Consultants and Medical Affairs representatives
  • View the presentations from Session 1 and 2 where our speakers discussed the history, testing strategies and current trends for MSI testing and why MSI status should be a universal testing approach
Speakers
  • Presenter headshot of Dr. Emily Teslow
    Dr. Emily Teslow,  Ph.D.
    Medical Science Liaison, Medical Affairs Dept, Promega Corporation
  • Presenter headshot of Dr. Kathryn Oostdik
    Kathryn Oostdik
    Sr. Global Product Manager, Clinical Diagnostics, Promega Corporation

Speakers
  • Kathryn Oostdik

    Sr. Global Product Manager, Clinical Diagnostics, Promega Corporation
    BIOGRAPHY
  • Dr. Emily Teslow, Ph.D.

    Medical Science Liaison, Medical Affairs Dept, Promega Corporation
    BIOGRAPHY
  • Dr. Ryan Nguyen, DO

    Chief Hematology and Oncology Fellow, University of Illinois at Chicago
    BIOGRAPHY
  • Dr. Samantha Lewis, Ph.D.

    Clinical Development Specialist, Promega Corporation
    BIOGRAPHY
  • Dr. Pamela Ward, Ph.D.

    Associate Professor of Clinical Pathology, Scientific Director, USC Clinical Laboratories, Molecular Pathology
    BIOGRAPHY
  • Jeff Bacher, PhD

    Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine
    BIOGRAPHY
  • James Eshleman, MD, PhD

    Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine
    BIOGRAPHY
  • Heather Hampel, MS

    LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center
    BIOGRAPHY
  • Gerard Blobe, MD, PhD

    Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine, Associate Director of Training and Education for the Duke Cancer Institute
    BIOGRAPHY

You May Also Like

Speakers

  • Performance of the OncoMateâ„¢ MSI Dx Analysis System
    Oct 26, 2021 12:00 PM CDT

    Performance of the OncoMateâ„¢ MSI Dx Analysis System

    Kathryn Oostdik
    Sr. Global Product Manager, Clinical Diagnostics, Promega Corporation
    BIOGRAPHY
  • Current Gold-Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker
    Oct 26, 2021 11:00 AM CDT

    Current Gold-Standards for MSI Testing and the Clinical Relevance of the MSI-H Biomarker

    Dr. Emily Teslow, Ph.D.
    Medical Science Liaison, Medical Affairs Dept, Promega Corporation
    BIOGRAPHY
  • Tracking MSI status in liquid biopsies from MSI-H colorectal cancer subjects on immunotherapy
    JUN 29, 2021 11:15 AM CDT

    Tracking MSI status in liquid biopsies from MSI-H colorectal cancer subjects on immunotherapy

    Dr. Pamela Ward, Ph.D.
    Associate Professor of Clinical Pathology, Scientific Director, USC Clinical Laboratories, Molecular Pathology
    BIOGRAPHY
  • Development of a Microsatellite Instability Assay Utilizing Novel Long Repeats
    JUN 29, 2021 10:40 AM CDT

    Development of a Microsatellite Instability Assay Utilizing Novel Long Repeats

    Dr. Samantha Lewis, Ph.D.
    Clinical Development Specialist, Promega Corporation
    BIOGRAPHY
  • Colorectal Cancer Disparities and the Role of MSI Testing and Implementation
    JUN 29, 2021 10:00 AM CDT

    Colorectal Cancer Disparities and the Role of MSI Testing and Implementation

    Dr. Ryan Nguyen, DO
    Chief Hematology and Oncology Fellow, University of Illinois at Chicago
    BIOGRAPHY
  • Clinical Testing and Implication of MSI Testing in GI Cancers

    Clinical Testing and Implication of MSI Testing in GI Cancers

    Gerard Blobe, MD, PhD
    Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine, Associate Director of Training and Education for the Duke Cancer Institute
    BIOGRAPHY
  • Universal Tumor Screening for Lynch Syndrome: Past, Present and Future

    Universal Tumor Screening for Lynch Syndrome: Past, Present and Future

    Heather Hampel, MS
    LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center
    BIOGRAPHY
  • MSI Predicts Immunotherapeutic Response

    MSI Predicts Immunotherapeutic Response

    James Eshleman, MD, PhD
    Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine
    BIOGRAPHY
  • Past, Present and Future: Advances in MSI Testing

    Past, Present and Future: Advances in MSI Testing

    Jeff Bacher, PhD
    Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine
    BIOGRAPHY
Agenda
On Demand Sessions

  • Colorectal Cancer Disparities and the Role of MSI Testing and Implementation
    Colorectal Cancer Disparities and the Role of MSI Testing and Implementation
    Dr. Ryan Nguyen, DO
    Chief Hematology and Oncology Fellow, University of Illinois at Chicago
    BIOGRAPHY
     
     
  • Development of a Microsatellite Instability Assay Utilizing Novel Long Repeats
    Development of a Microsatellite Instability Assay Utilizing Novel Long Repeats
    Dr. Samantha Lewis, Ph.D.
    Clinical Development Specialist, Promega Corporation
    BIOGRAPHY
     
     
  • Tracking MSI status in liquid biopsies from MSI-H colorectal cancer subjects on immunotherapy
    Tracking MSI status in liquid biopsies from MSI-H colorectal cancer subjects on immunotherapy
    Dr. Pamela Ward, Ph.D.
    Associate Professor of Clinical Pathology, Scientific Director, USC Clinical Laboratories, Molecular Pathology
    BIOGRAPHY
     
     
  • Clinical Testing and Implication of MSI Testing in GI Cancers
    Clinical Testing and Implication of MSI Testing in GI Cancers
    Gerard Blobe, MD, PhD
    Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine, Associate Director of Training and Education for the Duke Cancer Institute
    BIOGRAPHY
     
     
  • Universal Tumor Screening for Lynch Syndrome: Past, Present and Future
    Universal Tumor Screening for Lynch Syndrome: Past, Present and Future
    Heather Hampel, MS
    LGC Associate Director, Division of Human Genetics, Associate Director, Biospecimen Research Professor, Internal Medicine, Licensed Genetic Counselor, The Ohio State University Cancer Center
    BIOGRAPHY
     
     
  • MSI Predicts Immunotherapeutic Response
    MSI Predicts Immunotherapeutic Response
    James Eshleman, MD, PhD
    Professor of Pathology and Oncology, Associate Director, Molecular Diagnostics Laboratory, Johns Hopkins University School of Medicine
    BIOGRAPHY
     
     
  • Past, Present and Future: Advances in MSI Testing
    Past, Present and Future: Advances in MSI Testing
    Jeff Bacher, PhD
    Senior Research Scientist, Promega Corporation, Adjunct Professor, UW-Madison, Dept. of Medicine
    BIOGRAPHY
     
     

Help

Loading Comments...